Cardiovascular disease is the leading cause of death both globally and in the US. Each year it accounts for about 12% of total US healthcare expenditure.1 Incidence of cardiovascular disease, including hypertension, vascular disease, and heart failure, increases with age. In 2019, there were 54 million people aged 65 and older in the US, 18% of which reported having at least one cardiovascular condition;2 this age group is expected to grow to over 80 million people by 2040. Obesity is also a key contributor to cardiovascular disease, and a new class of GLP-1 weight loss drugs that appear to not only enable significant weight loss, but also reduce adverse cardiovascular events, is poised to significantly disrupt the cardiovascular care and technology industry.